-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CV-8102 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CV-8102 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CV-8102 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CV-7302 in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CV-7302 in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CV-7302 in Influenza A Virus, H1N1 Subtype...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CV-7302 in Influenza A Virus, H5N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CV-7302 in Influenza A Virus, H5N1 Subtype Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CV-7302 in Influenza A Virus, H5N1 Subtype...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CV-7302 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CV-7302 in Seasonal Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CV-7302 in Seasonal Influenza Drug Details: CV-7302 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVSQIV in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CVSQIV in Seasonal Influenza report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CVSQIV in Seasonal Influenza Drug Details: CVSQIV is under development for...
-
Product Insights
Seasonal Influenza Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Seasonal Influenza Clinical Trial Report Overview A total of 310 seasonal influenza clinical trials were conducted as of February 2024. The Seasonal Influenza clinical trial report provides a comprehensive understanding of the seasonal influenza clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Product Insights
NewYellow Fever – Drugs In Development, 2024
Empower your strategies with our Yellow Fever – Drugs In Development, 2024 report and make more profitable business decisions. Yellow fever is an acute systemic illness (hemorrhagic fever) caused by a flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeat, bleeding, vomiting, coma, delirium, fever, headache, and muscle aches. There is no specific treatment for yellow fever, so patients are treated to relieve the symptoms. The Yellow Fever drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewLassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Lassa Fever (Lassa Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes, and bleeding. The antiviral drug ribavirin seems to be an effective...
-
Product Insights
NewRotavirus Infections – Drugs In Development, 2024
Empower your strategies with our Rotavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these...
-
Product Insights
NewInfluenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment...